Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas
Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas
复制标题
DOI：
10.1186/1477-7819-8-52
复制
发表时间：
2010-06-26
影响因子：
3.2
通讯作者：
He, Xianli
中科院分区：
文献类型：
--
作者：
Bao, Guoqiang;Qiao, Qing;He, Xianli
简介：高迁移率族蛋白1（HMGB1），最初被描述为一种核蛋白，现在被认为是一种多功能蛋白，在肿瘤中具有矛盾的双重作用。本研究旨在探讨HMGB1过表达与胃腺癌临床病理特征及无复发生存期的关系。采用组织芯片技术检测HMGB1的表达。记录所有患者的临床病理特征，并定期随访。结果：HMGB1在胃癌组织中的阳性表达主要集中在细胞核内，且癌组织中HMGB1的表达强阳性率高于癌旁组织（总表达评分≥ 9分，42.0%对9.0%，P < 0.001）。生存分析显示，肿瘤分期与无癌生存率呈负相关（P = 0.022）。结论：HMGB1蛋白的高表达可能在胃腺癌的发生发展中起一定作用。HMGB1的过表达可能是胃癌根治性切除联合辅助化疗预后良好的一个标志。
Introduction: HMGB1(High mobility group box 1), originally described as a nuclear protein, is now regarded as a multifunctional protein with a paradoxical dual effect in tumors. In the present study, HMGB1 overexpression and its correlation with the clinicopathologic characteristics and recurrence-free survival were evaluated in gastric adenocarcinomas.Methods: 76 gastric adenocarcinomas surgically removed entered the study. The immunohistochemical staining was used to assess HMGB1 expression through tissue microarray procedure. The clinicopathologic characteristics of all patients were recorded, and the regular follow-up was made for all patients.Results: Almost all the gastric adenocarcinomas showed HMGB1 positive staining mainly in the nucleus, and the overexpression of HMGB1 was found in cancerous tissues with higher strong reactivity rate, compared with non-cancerous tissues (total expression score >= 9, 42.0% vs. 9.0%, P < 0.001). Survival analysis revealed that tumor stage negatively correlated with cancer-free survival (P = 0.022). Furthermore, HMGB1 overexpression positively associated with cancer-free survival of resectable gastric adenocarcinomas (P = 0.023).Conclusions: The overexpression of HMGB1 protein indicates that HMGB1 may play a role in the tumorigenesis of gastric adenocarcinomas. And the overexpression of HMGB1 may be a marker of good prognosis of gastric adenocarcinoma given curative resection combined with adjuvant chemotherapy.